131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA
Reports Second Quarter 2026 Financial Results and Provides Business Update
Termination of GSK Agreement for Progranulin-Elevating Antibodies
Alector, Inc. Annual Meeting Results; Class II Directors Elected
Alector, Inc. Enters $125 Million Sales Agreement with TD Cowen
Reports First Quarter 2026 Financial Results and Provides Business Update
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload
Definitive Revised Proxy Statement
S-1MEF